Eroding tolerance: A wonder drug shows us the drug industry’s fundamental failure to communicate

Apr 23

Drug PricingDrug PricesTrikaftaCystic FibrosisRA Capital AuthorquestsGCEAout-of-pocketsOOPsMarketingDTC

Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. Peter is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools and serves on the boards of publicly- and privately-held life science companies. Peter also leads the firm’s engagement and publishing efforts, which aim to make a positive social impact and spark collaboration among healthcare stakeholders, including patients, physicians, researchers, policymakers, and industry. He served on the Board of Global Science and Technology for the National Academy of Sciences, is the author of The Entrepreneur’s Guide to a Biotech Startup, and frequently writes and speaks on the future of biotechnology innovation. Peter founded and serves as a Director of No Patient Left Behind, a non-profit advocate for healthcare reforms that would make today's medicines affordable to patients and promote the innovation that gives all of us hope for tomorrow. He holds a BA from Cornell University and a PhD in Virology from Harvard University.

Eroding tolerance: A wonder drug shows us the drug industry’s fundamental failure to communicate

RAVen’s Project Condor fights flu with Cidara deal

Obvious in hindsight: On financings, pricing uncertainty, and early access to data